[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352550-105":59,"doc-detail-352550-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","immunotherapy-in-hepatocellular-carcinoma-translating-mechanistic-insights-into-clinical-advances","Immunotherapy in hepatocellular carcinoma - translating mechanistic insights into clinical advances","","Hepatocellular carcinoma is the most common primary liver cancer and a major cause of cancer-related mortality worldwide. Traditional systemic therapies, including tyrosine kinase inhibitors, provide limited survival benefit, leading to immunotherapy as a transformative approach. This review connects tumor microenvironment mechanisms to clinical outcomes from immune checkpoint inhibitor trials, covering monotherapy and combinations with antiangiogenic agents, radiotherapy, and locoregional treatments. It evaluates emerging vaccine, oncolytic, TLR agonist, and adoptive cell options, highlighting response subsets and key resistance pathways. It emphasizes managing immune-related adverse events, validating biomarkers, optimizing sequencing, and pursuing randomized studies to expand long-term survival gains.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunotherapy-in-hepatocellular-carcinoma-translating-mechanistic-insights-into-clinical-advances/352550/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunotherapy-in-hepatocellular-carcinoma-translating-mechanistic-insights-into-clinical-advances/352550.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is immunotherapy considered important for hepatocellular carcinoma?","Question",{"text":113,"@type":114},"Because traditional systemic therapies such as tyrosine kinase inhibitors provide limited survival benefits, immunotherapy has emerged as a transformative option with clinical trial support.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which immune checkpoint targets are emphasized in the review?",{"text":118,"@type":114},"Programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are highlighted as eliciting durable responses in subsets of patients.",{"name":120,"@type":111,"acceptedAnswer":121},"What factors contribute to resistance and treatment limitations in HCC?",{"text":122,"@type":114},"Resistance involves tumor-intrinsic mechanisms such as beta-catenin signaling and antigen presentation defects, as well as microenvironmental suppressive elements including regulatory T cells, myeloid-derived suppressor cells, and cytokine networks.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352550,1790378234,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Clinical and Experimental Medicine (2026) 26:181  \n[https://doi.org/10.1007/s10238-026-02099-2](https://doi.org/10.1007/s10238-026-02099-2)  \nREVIEW  \nImmunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances  \nSaeed Khavari Khorasani1 · Siavash Boroumandi2 · Ali Darzi3 · Mahla Shokouhfar3 · Pedram Abdali4 · Pooya Eini5 · Ahmad GhorbaniVanan6 · Nastaran Bahrami7,8  \nReceived: 24 November 2025 / Accepted: 10 February 2026 © The Author(s) 2026  \nAbstract  \nHepatocellular carcinoma is the most common primary liver cancer and a leading cause of cancer-related mortality worldwide. Traditional systemic therapies, such as tyrosine kinase inhibitors, offer limited survival benefits, prompting the emergence of immunotherapy as a transformative approach. This review synthesizes mechanistic insights into the tumor microenvironment of hepatocellular carcinoma with clinical evidence from pivotal trials on immune checkpoint inhibitors. It summarizes outcomes from monotherapy and combination regimens incorporating antiangiogenic agents, tyrosine kinase inhibitors, radiotherapy, and locoregional therapies like transarterial chemoembolization or hepatic arterial infusion chemotherapy. Emerging modalities, including therapeutic vaccines, oncolytic viruses, Toll-like receptor agonists, and adoptive cell therapies, are also examined. Immune checkpoint inhibitors targeting programmed cell death protein 1, its ligand, and cytotoxic T-lymphocyte-associated protein 4 elicit durable responses in subsets of patients, though monotherapy provides modest overall benefits. Combination strategies, such as atezolizumab plus bevacizumab, tremelimumab–durvalumab (STRIDE), and nivolumab plus ipilimumab (CheckMate-9DW), have set new standards of care by significantly extending overall survival with acceptable toxicity. Resistance mechanisms involve tumor-intrinsic factors like beta-catenin signaling and antigen presentation defects, alongside microenvironmental elements including regulatory T cells, myeloid-derived suppressor cells, and cytokine networks. Effective management of immune-related adverse events, particularly hepatic toxicities, is critical. Immunotherapy has revolutionized hepatocellular carcinoma treatment, fostering multimodal and personalized strategies. Future directions emphasize validated biomarkers, optimized sequencing, and randomized trials to broaden long-term survival gains.  \nKeywords Hepatocellular carcinoma · Immunotherapy · Immune checkpoint inhibitors · PD-1/PD-L1 · CTLA-4 · Tumor microenvironment · Combination therapy  \n\n| Ali Darzi and Mahla Shokouhfar are contributed equally to this work. |\n| --- |\n| Saeed Khavari Khorasani and Siavash Boroumandi are Co-first authors |\n\n􀀍 Ahmad Ghorbani Vanan[ghorbanivanan@sbmu.ac.ir](ghorbanivanan@sbmu.ac.ir)  \n􀀍 Nastaran Bahrami[nastaran.bahrami@srbiau.ac.ir](nastaran.bahrami@srbiau.ac.ir)  \n1 School of Medicine, Islamic Azad University, Bojnourd Branch, Bojnourd, North Khorasan, Iran  \n2 School of Medicine, Ardabil university of Medical Sciences, Ardabil, Iran  \n3 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n4 Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n5 Cardiovascular Research Center, Rajaie Cardiovascular Institute, Tehran, Iran  \n6 Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n7 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n8 Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran  \n1 3  \nIntroduction  \nHCC represents the leading primary cancer of the liver and represents a significant global health burden [1]. According to recent global cancer statistics, liver cancer ranks as the sixth most frequently diagnosed cancer and the third leading cause of","cbCaiouucGsGc8jT","https://ap.wps.com/l/cbCaiouucGsGc8jT","pdf",1999474,21,"English","# Abstract\n# Introduction\n## Epidemiology and global burden\n## Risk factors and chronic liver disease\n## Diagnosis approaches\n## Treatment challenges and resistance","[{\"question\":\"Why is immunotherapy considered important for hepatocellular carcinoma?\",\"answer\":\"Because traditional systemic therapies such as tyrosine kinase inhibitors provide limited survival benefits, immunotherapy has emerged as a transformative option with clinical trial support.\"},{\"question\":\"Which immune checkpoint targets are emphasized in the review?\",\"answer\":\"Programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are highlighted as eliciting durable responses in subsets of patients.\"},{\"question\":\"What factors contribute to resistance and treatment limitations in HCC?\",\"answer\":\"Resistance involves tumor-intrinsic mechanisms such as beta-catenin signaling and antigen presentation defects, as well as microenvironmental suppressive elements including regulatory T cells, myeloid-derived suppressor cells, and cytokine networks.\"}]","Immunotherapy in hepatocellular carcinoma - translating mechanistic insights into clinical advances | PDF",1790100224,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/271fe177a8432b2eddd7eef896cd58ce.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b72c4db1ef7a867348db5685f90462f3.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54ff255224590e20249565e1adbd21c0.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9d34bc2b0471a6b19bb317050bee8a0.webp",980,1301]